CSI Market
Sign In | Register

Niagen Bioscience Inc (NAGE) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NAGE Annual Cash Flow →
This page allows investors to follow Niagen Bioscience Inc's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income7.28
Depreciation & amortization0.23
Amortization of Other Assets0.35
Increase (Decrease) in Deferred Revenue-0.06
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.02
Increase (Decrease) in Inventories0.20
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Business4.76
Share-based Compensation3.44
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Goodwill And Intangible Asset Impairment-
Capital Lease Obligations Incurred-
Gain Loss On Non Recourse Debt-
Amortization Of Right of Use Assets-
Increase Decrease In Contract With Customer Asset-
Finance Lease Right Of Use Asset Amortization-
Loss From Investment In Long Term Assets-
Loss From Disposal Of Equipment-
Implementation Costs For Cloud Computing Arrangement-0.03
Operating Lease Right Of Use Asset Amortization Expense-
Increase Decrease In Contract With Customer Liability-0.10
Stockholders Equity-
Right Of Use Assets And Operating Lease Liabilities Reduced For Entering Into Lease Amendment-
Non Cash Lease Expense0.17
Interest Accretion On Deferred Consideration0.11
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables-1.14
Increase (Decrease) in Accounts Payable-1.36
Increase (Decrease) in Accrued Liabilities-3.88
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.52
Other Working Capital0.04
Other Noncash Income (Expense)-0.03
Other net0.00
Payments for (Proceeds from) Other Operating Activities-8.79
Discontinued operations0.00
Net Cash flow from Operating Activities1.58
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Sale Of Equipment-
Investment In Other Long Term Assets-
Payments For Transaction Costs From Sale Of Business-0.49
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses5.80
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-0.65
Discontinued operations0.00
Net Cash Flow from Investing Activities5.15
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-4.73
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.05
Cash Beginning Of Period-
Extinguishment Of Debt Gain Loss Net Of Tax-
Proceeds From Loans Payable-
Stock Repurchased And Retired During Period Value-
Finance Lease Principal Payments-
Proceeds From Sale Of Convertible Notes-
Settlement Of Deferred Consideration-0.05
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-4.78
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow1.58
Total Cash Flow1.95
4 historic quarters locked

Sign in to unlock the full Niagen Bioscience Inc cash flow history.

Sign In Create Free Account

About Niagen Bioscience Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001386570-26-000043

Figures are derived from filed reports and may be restated. Historical data is subject to revision.